Comment on the American Association of Oral and Maxillofacial Surgeons Statement on Bisphosphonates

Journal of Oral and Maxillofacial Surgery

Volumn 65, Issue 7, 2007, Pages 1440-1441

  Zahrowski, James J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; HISTAMINE H2 RECEPTOR ANTAGONIST; IBANDRONIC ACID; PAMIDRONIC ACID; PREDNISONE; RANITIDINE; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

BONE NECROSIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG ELIMINATION; ESOPHAGITIS; HUMAN; JAW DISEASE; LETTER; MEDICAL PERSONNEL; MEDICAL SOCIETY; OSTEOMYELITIS;

ADMINISTRATION, ORAL; ALVEOLAR PROCESS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INJECTIONS, INTRAVENOUS; JAW DISEASES; METABOLIC CLEARANCE RATE; OSTEONECROSIS; SOCIETIES, DENTAL;

EID: 34250180531     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2007.04.004     Document Type: Letter

References (24)

1. Marx R.E. Oral and Intravenous Bisphosphonate-Induced Osteonecrosis of the Jaws (2007), Quintessence Publishing Co, Hanover Park, IL
2. Zahrowski J.J. Bisphosphonate treatment: An orthodontic concern calling for a proactive approach. Am J Orthod Dentofacial Orthop 131 (2007) 313
3. Licata A.A. Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 39 (2005) 668
4. Lin J.H. Bisphosphonates: A Review of their pharmacokinetic properties. Bone 18 (1996) 75
5. Muhlbauer R.C., Bauss F., Schenk R., et al. BM21.0955, A potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6 (1991) 1003
6. In: Burnham T.H., and Wickersham R.M. (Eds). Drug facts and comparisons. 57th ed. (2003), Wolter Kluwer, St. Louis 336-349
7. Watts N.B. Treatment of osteoporosis with bisphosphonates. Endocrinol Metab Clin North Am 27 (1998) 419
8. Senel F.C., Tekin U.S., Durmus A., and Bagis B. Severe osteomyelitis of the mandible associated with the use of non-nitrogen containing bisphosphonate (disodium clodronate): Report of a case. J Oral Maxillofac Surg 65 (2007) 562
9. Santini D., Gentilucci U.V., Vicenzi B., et al. The antineoplastic role of bisphosphonates: From basic research to clinical evidence. Ann Oncol 14 (2003) 1468
10. Marx R.E., Sawatari J., Fortin M., and Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1567
11. Lacy M.Q., Dispenzieri A., Gertz M.A., et al. Mayo Clinic consensus for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 81 (2006) 1047
12. Mavrokokki T., Cheng A., Stein B., and Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65 (2007) 415
13. Prescribing information for Boniva (2006), Roche Laboratories Inc and GlaxoSmithKline, Research Triangle Park, NC
14. Prescribing information for Fosamax (2006), Merck & Co, Inc, Whitehouse Station, NJ
15. Hortobagyi G.N., Theriault R.L., Porter L., et al. Efficacy of pamidronate in reducing complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335 (1996) 1785
16. Meunier P.J., Arlot M., Chavassieux P., and Yates J. The effects of alendronate on bone turnover and bone quality. Int J Clin Pract 101 Suppl (1999) 14
17. Schimmer B.P., and Parker K.L. Adrenocorticotropic hormone; Adrenocortical steroids and their synthetic analogs; Inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman J.G., Limbird L.E., and Gilman A.G. (Eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th Ed. (2001), McGraw-Hill, New York 1667
18. Rodan G., Reszka A., Golub E., and Rizzoli R. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 20 (2004) 1291
19. Papapoulos S.E., and Cremers S.C. Prolonged bisphosphonate release after treatment in children. N Engl J Med 356 (2007) 1075
20. Porras A., Denker A., Santhanagopal A., et al. Alendronate and risedronate have similar pharmacokinetic half-lives when analyzed over the same time interval. J Bone Miner Res 18 (2003) S371
21. Sato M., Grasser W., Endo N., et al. Bisphosphonate action, alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88 (1991) 2095
22. Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., and Pak C.Y. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 90 (2005) 1294
23. Ensrud K.E., Barrett-Connor E.L., Schwartz A., et al. Randomized trial effect of alendronate continuation versus discontinuation in woman with low BMD results from the fracture intervention trial long term extension. J Bone Miner Res 19 (2004) 1259
24. Black D.M., Schwartz A.V., Ensrud K.E., Cauley J.A., Levis S., and Quandt S.A. Effects of continuing or stopping alendronate after 5 years of treatment. JAMA 296 (2006) 2927